DRMA
Dermata Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About DRMA
Dermata Therapeutics, Inc.
A clinical-stage biotech company focusing on the treatment of medical and aesthetic skin conditions
3525 Del Mar Heights Rd., #322, San Diego, CA 92130
--
Dermata Therapeutics, Inc., in Delaware in December 2014. They are a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative drug candidates for the treatment of medical and aesthetic skin diseases and conditions, which the company believes represent a significant market opportunity due to the lack or non-existence of current therapies.
Company Financials
EPS
DRMA has released its 2023 Q3 earnings. EPS was reported at -0.54, versus the expected -0.63, beating expectations. The chart below visualizes how DRMA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available